Shares of EchoIQ Ltd (EIQ.AU) plummeted 5.68% during intraday trading on Tuesday, marking a significant downturn for the artificial intelligence diagnostics company.
The decline follows the publication of analyst commentary suggesting the company's share price may be overvalued. A recent report highlighted EchoIQ's current financial metrics, including a net loss of A$8.66 million for the last half year and revenue of just A$0.09 million, leading to the assessment that its market valuation might be overly optimistic despite forecasts for high future growth.
Concurrently, the company announced the deployment of its Echosolv AI diagnostic tool into the Mount Sinai Health System. However, this positive operational development appears to have been overshadowed by investor focus on valuation concerns raised by market analysts.